Sigrid Therapeutics Announces SiPore15TM Selected for Oral Presentation at Upcoming 28th European Diabetics Congress in Edinburgh
Novel silica particle-based therapy significantly reduces blood sugar and other metabolic risk factors
Stockholm, Sweden, 21 May 2019 – Sigrid Therapeutics AB, a biotechnology company developing a new class of therapies for metabolic diseases and disorders, today announces that the Company’s first in class medical device, SiPore15TM, has been selected for oral presentation in the Advanced Technologies Track at the 28th European Diabetics Congress, July 17-18, 2019 in Edinburgh, UK. Based on a specially engineered mesoporous silica particle (MSP), SiPore15TM is designed to treat the growing number of prediabetics and newly diagnosed diabetics by significantly reducing blood sugar, blood lipids and body fat composition.
Entitled “Entrapping Digestive Enzymes with Engineered Silica Particles Reduces Metabolic Risk Factors”, the presentation will highlight SiPore15TM’s mode of action along with the growing body of clinical evidence from the ongoing trials program. The presentation will be given by Dr. Erik Waara, Head of Pre-Clinical Development at Sigrid Therapeutics.
“We are delighted to be invited to present details of SiPore15TM in Edinburgh and demonstrate how it meets the congress theme “Recent Advancements and Developments for Changing Life of Diabetes World”. With 1 in 11 adults already affected in Europe and the overall diabetic population predicted to rise to 68.9 million by 2035 according to the International Diabetes Federation (IDF) there is an urgent need for new approaches. We believe SiPore15TM has the potential to prevent and treat type 2 diabetes in a novel and safer way”, comments Professor Tore Bengtsson, Co-founder and Chief Scientific Officer at Sigrid Therapeutics.
Data from a second trial, prediabetic/type 2 diabetes patients (n=40) will be reported in the second half of 2019 (clinicaltrials.org ID no. NCT03823027).
About Sigrid Therapeutics AB
Sigrid Therapeutics AB (Sigrid) is a Swedish clinical-stage biotechnology company whose lead product candidate is SiPore15TM, a precisely engineered orally ingested material, acting locally in the gut. The material is protected by filed IP and produced to cGMP standards. SiPore15TM is the lead product candidate based on Sigrid’s proprietary platform technology SiPoreTM. Solutions based on the SiPoreTM technology have the potential to become breakthrough therapies for a range of preventable metabolic disorders and diseases with high unmet clinical need.